Cybin (HELP) Other Operating Expenses (2020 - 2026)
Cybin's (HELP) quarterly Other Operating Expenses came in at $5.3 million in Q1 2026, down 82.39% YoY from $29.8 million in Q1 2025, and up 17.4% on a QoQ basis from $4.5 million in Q4 2025.
Cybin (HELP) Other Operating Expenses (2020 - 2026) Analysis & Trends
Cybin (HELP) has 7 years of Other Operating Expenses data on file, last reported at $5.3 million in Q1 2026.
- Quarterly Other Operating Expenses fell 82.39% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (down 63.64% YoY) and the FY2026 annual result came in at $10.9 million, down 65.27% from the prior year.
- Other Operating Expenses climbed to $5.3 million in Q1 2026, from $4.5 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $29.8 million in Q1 2025 to a low of -$16.6 million in Q1 2023.
- A 5-year average of $2.4 million and a median of $200764.4 in 2024 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2022 — Other Operating Expenses sank 135.3% — and 2025, when it jumped 187036.78%.
- Tracing HELP's Other Operating Expenses over 5 years: stood at -$21.0 in 2022, then surged by 34826.04% to $7292.5 in 2023, then plunged by 67.19% to $2392.4 in 2024, then jumped by 187036.78% to $4.5 million in 2025, then advanced by 17.4% to $5.3 million in 2026.
- The last three Other Operating Expenses figures came in at $5.3 million (Q1 2026), $4.5 million (Q4 2025), and $377000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.26 Mn |
| Dec 31, 2025 | 4.48 Mn |
| Sep 30, 2025 | 377,000.00 |
| Jun 30, 2025 | 753,000.00 |
| Mar 31, 2025 | 29.85 Mn |
| Dec 31, 2024 | 2,392.37 |
| Sep 30, 2024 | 24,528.70 |
| Jun 30, 2024 | 2,123.23 |
| Mar 31, 2024 | 10.30 Mn |
| Dec 31, 2023 | 7,292.47 |
| Sep 30, 2023 | 1,054.75 |
| Jun 30, 2023 | 949,176.89 |
| Feb 28, 2023 | -16.60 Mn |
| Sep 30, 2022 | -21.00 |
| May 31, 2022 | 2.80 Mn |
| Mar 31, 2022 | -1,436.00 |
| Dec 31, 2021 | -695.00 |
| Sep 30, 2021 | -506,038.73 |
| Jun 30, 2021 | -497.88 |
| Mar 31, 2021 | 4,068.00 |